Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022
Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022
Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer
Read more at globenewswire.com